Jul 12, 2023
Data on a new crop of hormone analogues for weight
loss—including an oral version of semaglutide and the triple agent
retatrutide—were recently presented at the American Diabetes
Association’s annual Scientific Sessions. Robert Gabbay, MD, PhD,
the ADA’s chief scientific and medical officer, speaks with JAMA’s
Jennifer Abbasi about this and other clinical data presented at the
meeting.
Related Content: